Autopsy report · NCT00285051

Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

“Study drug expiry date not extended”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 3 years 3 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Rafa Laboratories

Sponsor type

Industry

Conditions

Cancer

Interventions

inhaled delta-8-THC 300mcg or 600mcg per dose

Participants

6

Sites

2

Countries

Israel

Trials that died the same way

• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (71% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (66% match in meaning)
• Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs
  “Medication expired” (64% match in meaning)
• An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
  “Study medication was no longer available for study” (62% match in meaning)
• Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
  “Drug expired and access to additional supply ended. PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.